James B. Young

TL;DR: The Interagency Registry For Mechanical Circulatory Support, an NHLBI-sponsored collaboration between the National Heart, Lung, and Blood Institute, the Food and Drug Administration, the Center for Medicaid and Medicare Services, and the advanced heart failure/mechanical circulatory support professional community, began prospective patient enrollment and data collection on June 23, 2006.

TL;DR: In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief and was associated with an increased risk of adverse cardiovascular events.

TL;DR: A study of 6,273 consecutive relatively unselected patients with heart failure or left ventricular dysfunction, or both (mean age 62 +/- 12 years, mean ejection fraction 31 +/- 9%), were enrolled in the Studies of Left Ventricular Dysfunction (SOLVD) Registry over a period of 14 months.

TL;DR: Although corticosteroids continue to be used as maintenance immunosuppression for most recipients prior to discharge, there is evidence that efforts of steroid avoidance protocols are having an impact across all organs, as slight decreases in their use have been observed.

TL;DR: Clinical data support current professional society guidelines to not discontinue ACEIs or ARBs in the setting of the COVID-19 pandemic, and overlap propensity score weighting showed no significant association of ACEI and/or ARB use with CO VID-19 test positivity.